Traders should monitor the closing of the acquisition in Q2 2026 and subsequent integration progress. The immediate accretion to EBITDA and strong synergy target suggest potential upside to earnings, while the use of debt increases leverage, watch for updates on financing and integration efficiency.
COLL drugs
COLL drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 19 $36.30entry
- T+1 · 8mo ago −2.37%α −0.63% · $35.44
- T+5 · 8mo ago −7.93%α −5.72% · $33.42
- T+20 · 7mo ago −5.21%α −12.83% · $34.41
- T+60 · 5mo ago −5.81%α −20.16% · $34.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Collegium Pharmaceutical is acquiring AZSTARYS, a differentiated ADHD treatment, from Corium Therapeutics for $650 million in cash plus up to $135 million in milestone payments. The deal expands Collegium’s ADHD portfolio, is expected to be immediately accretive to adjusted EBITDA, and will be funded with cash on hand and a $300 million delayed draw term loan. AZSTARYS is projected to generate over $50 million in pro forma net revenue in the second half of 2026.
Key Financial Metrics
Key Facts
- Collegium is acquiring AZSTARYS for $650 million in cash, with potential milestone payments up to $135 million.
- AZSTARYS is a CNS stimulant for ADHD with dual-release mechanism and expected patent protection into 2037.
- The acquisition is expected to be immediately accretive to adjusted EBITDA and generate over $50 million in pro forma net revenue in second half 2026.
- Deal to be funded with cash on hand and $300 million delayed draw term loan; net leverage expected at ~2x post-close.
- Transaction expected to close in Q2 2026, subject to regulatory approvals including Hart-Scott-Rodino.
Financial Impact
$650 million upfront payment with $135 million in potential milestones; expected to add over $50 million in net revenue in second half of 2026 and generate over $50 million in annual run-rate synergies within 12 months.
Risk Factors
- Regulatory delays or failure to obtain HSR approval could delay or block the transaction.
- Integration risks could prevent realization of projected $50M+ synergies.
- Increased leverage (though moderate at ~2x) adds financial risk if AZSTARYS underperforms expectations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258918 |
Track record
24 reports on COLL
1 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
- Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
- Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers